HERATYS is a marketing authorisation holder and pharmaceutical company specialised in the commercial and regulatory revitalisation of mature, underexploited, or discontinued brands.

Our goal is clear: to bring proven medicines back to life — products that are no longer a strategic priority for major pharmaceutical companies.

Thanks to our sector expertise, strong partner network, and in-depth market knowledge, we give essential therapeutic products a second commercial life — by repositioning them with agility in the markets where they remain vital. 

HERATYS stands out for its ability to act swiftly, adapt to local realities, and offer flexible collaboration models — ranging from full acquisition to exclusive licensing. 

We are far more than just brand acquirers: we are builders of therapeutic continuity, dedicated to meeting the real needs of communities. 

HERATYS — A Winning Partnership

The success of a pharmaceutical company rests on two key factors :

• Maintaining product availability on the market;
• Industry expertise across all stages of the value chain.

HERATYS’s strength stems from the synergy between UbiPharm and Ylancia Conseil, its two shareholders.